glp 1 and trump Freezes as GLP-1 Patient Collapses Right Behind Him in Oval Office Trump, Eli Lilly, Novo Nordisk

The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes

To address this growing global challenge, the World Health Organization (WHO) has developed a guideline on the use of glucagon-like peptide-1 (GLP-1) based therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for adults living with obesity.Join us at the virtual launch event in a webinar hosted by WHO in collaboration with the Journal of the American Medical Association (JAMA) on 1 December 2025 at 16:00 CET

March 25, 2024

Managing a routine that involves two pens whether you're rotating between an active and backup pen, using different pens for different compounds, or combining a GLP-1 pen with a hormone pen means carrying more supplies than a single-pen case can handle

Eradication of H

Among new antidiabetic medicines, the market share of DPP-4 inhibitors was the highest